Devices, assemblies and methods for delivering fluid formulations into gastrointestinal tract
By designing a fluid formulation delivery device for GI channels, the synergistic effect of shell, piston-needle assembly, membrane and valve member is solved, poor enzyme decomposition and tolerance of macromolecular drugs in the existing drug delivery routes are solved. The problem of this has achieved efficient delivery of large doses of therapeutic agents, and improved drug compliance and quality of life.
Patent Information
- Application Number
- CN202380028660.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-21
- Filing Date
- 2023-02-18
- Publication Date
- 2024-11-08
AI Technical Summary
Existing routes of administration such as intake and parenteral injection have problems such as enzyme decomposition of large molecules in the gastrointestinal tract, poor tolerance and pain, which limits the delivery of high-dose therapeutic agents, especially solid dosage forms are suitable for small doses, which is difficult to Meet higher dose needs.
A device including a housing, a piston-needle assembly, a membrane and a valve member is designed to deliver up to 400 microliters of a fluid formulation, which is opened through the movement control valve member of the piston-needle assembly, and the fluid formulation flows from the reservoir into the chamber. and guided into the GI lumen wall or surrounding tissue to achieve the delivery of large doses of therapeutic agents.
The device allows effective delivery of a large dose range of therapeutic agents, addressing the disadvantages of conventional oral and parenteral routes of administration, achieving efficient drug delivery, and improving medication compliance and quality of life.
Smart Images

Figure CN118922224A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of and priority to U.S. Provisional Application No. 63 / 312,355, filed on February 21, 2022, the entire contents of which are hereby incorporated by reference herein.
[0003] background
[0004] Therapeutic agents (such as drugs) can be administered to subjects by ingestion or by parenteral injection (e.g., subcutaneous, intramuscular or intravenous injection) to provide a desired therapeutic effect. However, these routes of administration have some disadvantages. For example, some therapeutic agents such as large (high) molecules are not suitable for delivery by ingestion because these molecules are enzymatically decomposed in the subject's gastrointestinal (GI) tract. Other types of therapeutic agents may be poorly tolerated in the GI tract, resulting in low systemic intake. For parenteral injection, subjects may experience pain and inconvenience in administration, which may significantly affect medication compliance and quality of life.
[0005] In order to address these shortcomings, ingestible devices have been proposed for oral delivery of therapeutic agents in solid form to the lumen wall of the GI tract or surrounding tissues. However, solid dosage forms may be limited to relatively small doses (e.g., a few milligrams). Therefore, due to, for example, dosing frequency, convenience or cost, the use of solid dosage forms may be disadvantageous for treatment regimens requiring higher doses.
[0006]
[0006] Therefore, there is a need for devices that are capable of delivering a wide range of dosages of therapeutic agents and that address one or more of the disadvantages associated with conventional oral and parenteral routes of administration.
[0007] Overview
[0008] Embodiments disclosed herein generally relate to devices, assemblies and methods for delivering fluid preparations to the GI tract of a subject (e.g., in the GI luminal wall or surrounding tissue). The device and assembly are configured to deliver up to about 400 microliters (μl) or more of fluid preparations, which may include up to about 100mg or more of at least one therapeutic agent of dosage. In this way, disclosed devices, assemblies and methods may allow for effective delivery of therapeutic agents in large dose ranges for most treatment regimens.
[0009] In one aspect, a delivery assembly for an ingestible device, for delivering a fluid preparation to a subject's GI luminal wall or surrounding tissue, comprises a housing, a piston-needle assembly, a membrane and a valve member. The housing defines a chamber. The piston-needle assembly is movably disposed in the chamber and comprises an inlet and a passage. The membrane is coupled to the housing so that the membrane and the housing cooperatively define a reservoir for accommodating the fluid preparation. The housing also defines an opening extending between the chamber and the reservoir. The valve member selectively controls the flow of the fluid preparation from the reservoir to the chamber through the opening. In response to the piston-needle assembly fully moving relative to the housing, the valve member opens to allow the fluid preparation to flow into the chamber from the reservoir through the opening. The fluid preparation is guided to the inlet and passage from the chamber to be delivered to the GI luminal wall or its surrounding tissue.
[0010] On the other hand, a kind of ingestible device for delivering fluid preparation to the GI luminal wall or surrounding tissue of a subject comprises an expandable member and a delivery assembly connected to the expandable member and arranged in the expandable member. The delivery assembly comprises a housing, a piston-needle assembly, a membrane, a fluid preparation and a valve member. The housing defines a chamber. The piston-needle assembly is movably arranged in the chamber and comprises an inlet and a passage. The membrane is connected to the housing so that the membrane and the housing cooperatively define a reservoir. The housing also defines an opening extending between the chamber and the reservoir. The fluid preparation is arranged in the reservoir and comprises at least one therapeutic agent. The valve member selectively controls the flow of the fluid preparation from the reservoir to the chamber through the opening. In response to the sufficient movement of the piston-needle assembly relative to the housing, the valve member opens to allow the fluid preparation to flow into the chamber from the reservoir through the opening. The fluid preparation is guided to the inlet and the passage from the chamber to be delivered to the GI luminal wall or its surrounding tissue.
[0011] On the other hand, a method for delivering a fluid preparation to a GI luminal wall or surrounding tissue of a subject in need includes ingesting an ingestible device as described herein by the subject. The ingestible device includes an expandable member and a delivery assembly coupled to the expandable member and disposed in the expandable member. The delivery assembly includes a housing, a piston-needle assembly, a membrane, a fluid preparation, and a valve member. The housing defines a chamber. The piston-needle assembly is movably disposed in the chamber and includes an inlet and a passage. The membrane is coupled to the housing so that the membrane and the housing cooperatively define a reservoir. The housing also defines an opening extending between the chamber and the reservoir. The fluid preparation is disposed in the reservoir and includes at least one therapeutic agent. The valve member selectively controls the flow of the fluid preparation from the reservoir to the chamber through the opening. In response to sufficient movement of the piston-needle assembly relative to the housing, the valve member opens to allow the fluid preparation to flow from the reservoir into the chamber through the opening. The fluid preparation is guided to the inlet and passage from the chamber to be delivered to the GI luminal wall or its surrounding tissue.
[0012] On the other hand, a use of an ingestible device for delivering a fluid preparation to a GI luminal wall or surrounding tissue of a subject in need thereof, including ingesting an ingestible device as described herein by a subject. The ingestible device includes an expandable member and a delivery assembly coupled to the expandable member and disposed in the expandable member. The delivery assembly includes a housing, a piston-needle assembly, a membrane, a fluid preparation, and a valve member. The housing defines a chamber. The piston-needle assembly is movably disposed in the chamber and includes an inlet and a passage. The membrane is coupled to the housing so that the membrane and the housing cooperatively define a reservoir. The housing also defines an opening extending between the chamber and the reservoir. The fluid preparation is disposed in the reservoir and includes at least one therapeutic agent. The valve member selectively controls the flow of the fluid preparation from the reservoir to the chamber through the opening. In response to sufficient movement of the piston-needle assembly relative to the housing, the valve member opens to allow the fluid preparation to flow from the reservoir into the chamber through the opening. The fluid preparation is guided from the chamber to the inlet and passage to be delivered to the GI luminal wall or its surrounding tissue.
[0013] In another aspect, a method of preparing an ingestible device for delivering a therapeutic agent to the GI lumen wall or surrounding tissue of a subject is provided, the method comprising filling a fluid formulation comprising the therapeutic agent into a delivery component as described herein.
[0014] In one or more embodiments of any one of the preceding aspects, the piston-needle assembly and the housing cooperatively define a fluid passage within the chamber for directing the fluid formulation from the opening to the inlet.
[0015] In one or more embodiments of any one of the foregoing aspects, the valve member includes a plug removably coupled to the housing at the opening. In one or more embodiments, the piston-needle assembly engages the plug to separate the plug from the housing to allow the fluid formulation to flow from the reservoir through the opening into the chamber.
[0016] In one or more embodiments described in any one of the foregoing aspects, the valve member includes a piercing member and a seal, and wherein the seal is coupled to the housing at the opening. In one or more embodiments, the piston-needle assembly engages the piercing member so that the piercing member pierces the seal, thereby allowing the fluid formulation to flow from the reservoir through the opening into the chamber. In one or more embodiments, the piercing member is configured as a flexible tab with a tapered end. In one or more embodiments, the piercing member is configured as an elongated shaft with a tapered end.
[0017] In one or more embodiments of any one of the preceding aspects, the device further comprises an ingestible housing for delivery to the GI tract of a subject.
[0018] In one or more embodiments of any one of the preceding aspects, the expandable member comprises a balloon.
[0019] In one or more embodiments of any one of the preceding aspects, the device further comprises a plurality of reactants disposed in the balloon for generating gas pressure within the balloon to expand the balloon within the GI lumen.
[0020] In one or more embodiments described in any of the preceding aspects, the piston-needle assembly is configured to move relative to the housing in response to gas pressure applied to a surface of the piston-needle assembly to advance a portion of the piston-needle assembly into the GI lumen wall or surrounding tissue thereof.
[0021] In one or more embodiments of any one of the preceding aspects, the membrane comprises a flexible material to allow the membrane to be deformed by gas pressure applied to an outer surface of the membrane to expel the fluid formulation from the reservoir into the chamber.
[0022] In one or more embodiments of any one of the preceding aspects, the piston-needle assembly is configured to penetrate the GI lumen wall into the peritoneum or peritoneal cavity of the subject to discharge the fluid formulation in the peritoneum or peritoneal cavity.
[0023] In one or more embodiments of any one of the preceding aspects, the reservoir defines a volume for accommodating up to about 400 μl of fluid.
[0024] In one or more embodiments of any one of the preceding aspects, the reservoir defines a volume for containing about 50 μl to about 300 μl of fluid.
[0025] In one or more embodiments of any of the preceding aspects, the delivery assembly further comprises a cap coupled to the housing, the cap defining a release mechanism for temporarily retaining the piston-needle assembly in an axial position relative to the housing.
[0026] In one or more embodiments described in any one of the preceding aspects, the cover includes a first cover segment connected to the housing and a second cover segment connected to the piston-needle assembly, and wherein the release mechanism is defined by one or more tabs detachably connected between the first cover segment and the second cover segment.
[0027] In one or more embodiments described in any one of the preceding aspects, the cover further comprises one or more openings to allow gas pressure to be applied to the surface of the piston-needle assembly, and wherein the one or more tabs are configured to separate from at least one of the first cover segment or the second cover segment to allow the piston-needle assembly to move axially relative to the housing in response to the gas pressure reaching a threshold value.
[0028] In one or more embodiments of any one of the preceding aspects, the membrane extends circumferentially around the housing.
[0029] In one or more embodiments of any one of the preceding aspects, the housing comprises one or more fill ports for filling the reservoir with the fluid agent.
[0030] In one or more embodiments of any one of the preceding aspects, the delivery assembly further comprises a fluid formulation disposed in the reservoir, wherein the fluid formulation comprises at least one therapeutic agent.
[0031] In one or more embodiments of any of the foregoing aspects, at least one therapeutic agent is selected from one or more of an immunosuppressive drug, a chemotherapeutic drug, a central nervous system (CNS) drug, an anti-diabetic drug, an enzyme replacement therapy (ERT) drug, an antibody, a hormone, insulin, an incretin or a combination thereof, or an oligonucleotide.
[0032] The foregoing general description and the following detailed description are provided by way of example and are intended to provide further explanation of the disclosure claimed without limiting the disclosure or the claims. Other objects, advantages and novel features will be apparent to those skilled in the art from the following brief description of the drawings and the detailed description of the disclosure. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 An embodiment of a device for delivering a fluid formulation to the GI tract of a subject is shown in block diagram form.
[0035] Figure 2 Shows Figure 1 A cross-sectional view of an embodiment of a device.
[0036] Figure 3 The delivery component is shown Figure 2 Detailed view of a portion of the device.
[0037] Figure 4 Shown without membrane Figure 3 A partial perspective view of the delivery assembly.
[0038] Figure 5 Shown without membrane Figure 3Another partial perspective view of the delivery assembly.
[0039] Figure 6 The device is shown in a second state when it has reached a desired location in the GI tract to deliver a fluid formulation. Figure 3 device.
[0040] Figure 7 A perspective view of a valve member in the form of a piercing member according to an exemplary embodiment is shown.
[0041] Figure 8 Shows that there is Figure 7 The piercing member Figure 2 A partial cross-sectional view of the device.
[0042] Figure 9-10 A valve member in the form of a plug according to another exemplary embodiment is shown. Figure 2 device.
[0043] Fig.11 Methods of delivering a fluid formulation to the GI tract of a subject using the devices and assemblies of the present disclosure are presented.
[0044] Detailed Description
[0045] Before discussing the details of the apparatus, assemblies, and methods of the present disclosure, some generalizations are provided for the convenience of the reader.
[0046] When used in the present disclosure, the terms "eg," "such as," "for example," "for an example," "for another example," "an example of," "for example," and "etc." indicate that one or more non-limiting examples are listed preceding or following; it should be understood that other examples not listed are also within the scope of the present disclosure.
[0047] As used herein, the singular terms "a", "an", and "the" may include plural references unless the context clearly dictates otherwise. Any reference to an object in the singular is not intended to mean "one and only one", unless explicitly stated as such, but rather means "one or more".
[0048] As used herein, phrases in the form “A / B” or “A and / or B” mean (A), (B), or (A and B); phrases in the form “at least one of A, B, or C” mean (A), (B), (C), (A and B), (A and C), (B and C), or (A, B, and C).
[0049] The term "in an embodiment" or variations thereof (e.g., "in another embodiment" or "in an embodiment") refers to use in one or more embodiments herein, and in no case limits the scope of the present disclosure to only the illustrated and / or described embodiments. Thus, components shown and / or described herein with respect to an embodiment may be used in another embodiment (e.g., in another embodiment shown and described herein, or in another embodiment within the scope of the present disclosure and not shown and / or described herein).
[0050] The term "component" refers herein to an item in a group of one or more items, which together constitute the device, composition or system in question. A component may be a solid, powder, gel, plasma, fluid, gas or other composition. For example, a device may include a plurality of solid components that are assembled together to form the device, and may also include a liquid component disposed in the device. For another example, a composition may include a single component, or two or more components that are mixed together to prepare a composition. A composition may be in the form of a fluid, a slurry, a powder or a solid (e.g., in a concentrated or consolidated form, such as a tablet or microtablet). A device or system may include one or more compositions and / or one or more other components.
[0051] The term "design" or its grammatical variations (e.g., "designing" or "designed") refers herein to properties that are intentionally incorporated based on estimates of, for example, tolerances (e.g., component tolerances and / or manufacturing tolerances) and environmental conditions expected to be encountered (e.g., temperature, humidity, external or internal environmental pressures, external or internal mechanical pressures, stresses from external or internal mechanical pressures, product age or shelf life, or if introduced into the body, physiology, body chemistry, biological composition of fluids or tissues, chemical composition of fluids or tissues, pH, species, diet, health, sex, age, ancestry, disease, or tissue damage); it is understood that actual tolerances and environmental conditions before and / or after delivery can affect the properties, such that different components, devices, compositions, or systems having the same design can have different actual values for those properties. Design also includes changes or modifications before or after manufacture.
[0052] The term "structured" or its grammatical variations (e.g., "structure" or "structuring") as used herein refers to a component, device, composition or system manufactured according to a concept or design, or variations or modifications thereof (whether such variations or modifications occur before, during or after manufacture), whether or not such concept or design is recorded in writing.
[0053] Unless the context clearly dictates otherwise, the term "body" as used herein refers to the animal body.
[0054] The term "subject" refers herein to a body to which embodiments of the present disclosure are delivered or intended to be delivered. For example, in the case of humans, a subject may be a patient being treated by a health care professional. The terms "individual," "subject," and "patient" are used interchangeably herein and refer to any individual animal subject (e.g., cattle, dogs, cats, horses, or humans). In specific embodiments, the subject, individual, or patient is a human.
[0055] The term "fluid" herein refers to a liquid or a gas, and includes moisture and humidity. The term "fluid environment" herein refers to an environment in which one or more fluids are present.
[0056] The term "ingest" or grammatical variations thereof (e.g., "ingesting," "ingestion," or "ingested") refers herein to entry into the stomach, whether by swallowing or by other deposition into the stomach (e.g., endoscopic deposition into the stomach or deposition into the stomach via a port).
[0057] The term "degrade" or its grammatical variations (e.g., "degrading," "degraded," "degradable," and "degradation") herein refers to weakening, partial degradation, or complete degradation, such as by dissolution, chemical degradation (including biodegradation), decomposition, chemical modification, mechanical degradation, or disintegration, which also includes, but is not limited to, dissolution, fragmentation, deformation, shrinkage, or contraction. The term "non-degradable" refers to the expectation that degradation will be minimal or within some acceptable design percentage in the expected environment for at least the expected duration.
[0058] The term "degradation rate" or its grammatical variants (e.g., "rate of degradation") refers herein to the rate at which a material degrades. In particular embodiments, the designed degradation rate of a material can be defined by the rate at which the material is expected to degrade under expected conditions (e.g., under physiological conditions) at the target delivery site. The designed degradation time for a particular embodiment can refer to the designed time for complete degradation or the designed time for partial degradation sufficient to achieve the designed purpose (e.g., destruction). Thus, for example, the designed degradation time can be specific to a component and / or specific to the expected conditions at the target delivery site. The designed degradation time can be short or long and can be defined in terms of an approximate time, a maximum time, or a minimum time.
[0059] The term "substantially" is used herein to describe and account for small variations that may result from, for example, manufacturing or assembly processes. For example, when used in conjunction with a numerical value, the term may refer to a variation of less than or equal to ±10% of the value.
[0060] The term "lumen" herein refers to the interior space of a tubular structure. Examples of lumens in the body include arteries, veins, and tubular cavities within organs.
[0061] The term "luminal wall" refers to the wall of a lumen, wherein the wall includes all layers from the inner periphery to the outer periphery of the lumen, such as the mucosa, submucosa, muscularis, serosa and outer wall of the lumen relative to the lumen of the body, as well as constituent blood vessels and tissues.
[0062] The term "gastrointestinal tract" or "GI tract" refers herein to the body's ingestion / excretion system including, for example, the mouth, pharynx, esophagus, stomach, pylorus, small intestine, cecum, large intestine, colon, rectum, anus, and valves or sphincters therebetween.
[0063] The term "GI lumen" generally refers to any lumen of the GI tract (eg, the lumen of the esophagus, stomach, small intestine, large intestine, or colon), and the term "GI lumen wall" refers to the luminal wall of the GI lumen.
[0064] As used herein, the terms "comprising," "comprise," "includes," and "including" are intended to mean that compositions and methods include the listed elements, but not excluding other elements.
[0065] With general reference to the accompanying drawings, embodiments of devices, assemblies and methods for delivering fluid preparations to the lumen wall or surrounding tissues (e.g., peritoneum or peritoneal cavity) of the GI tract of a subject are disclosed herein. The device is advantageously configured to store one or more therapeutic agents in the fluid preparations in the GI tract for delivery to the GI lumen wall or its surrounding tissues. Delivery to the GI lumen wall or surrounding tissues can allow systemic uptake of one or more therapeutic agents in the fluid preparations. In addition, for most treatment regimens, preparations in fluid form can allow delivery of one or more therapeutic agents of a wide range of doses (e.g., up to about 100 mg or more). As discussed below, the disclosed device and assembly can deliver a variety of different types of therapeutic agents, such as macromolecules that are generally not suitable for delivery by ingestion. In this way, the disclosed device, assembly and method solve many shortcomings associated with conventional oral and parenteral administration routes.
[0066] Figure 1 An example of a device 100 according to one or more embodiments of the present disclosure is shown in block diagram form. The device 100 includes a housing 102, an optional outer coating 104, an expandable member 106, a release member 108, and a delivery assembly 110. The delivery assembly 110 includes a housing 112, a membrane 114, a fluid formulation 116, a valve member 118, and a piston-needle assembly 120.
[0067] According to non-limiting examples, the housing 102 (or optionally the housing 102 and / or the outer coating 104) can be degraded at a desired location in the GI tract (e.g., the stomach or small intestine) of a subject to deliver the fluid formulation 116, as described in more detail below. As described in more detail below, in response to at least partial degradation of the housing 102 and / or the outer coating 104, the release member 108 is activated to cause a chemical reaction within the expandable member 106, resulting in the formation of gas to cause the expandable member 106 to expand. The expansion of the expandable member 106 within the GI lumen causes the delivery assembly 110 to be positioned close to (e.g., adjacent to or in contact with) the lumen wall. When the internal pressure generated by the gas within the expandable member 106 reaches a threshold value (e.g., when the expandable member 106 expands), the gas pressure moves the piston-needle assembly 120 relative to the housing 112 to advance a portion of the piston-needle assembly 120 into the GI lumen wall. The internal pressure generated by the gas is also applied to the outer surface of the membrane 114 before the fluid formulation 116 is expelled into the chamber of the housing 112 for subsequent delivery into the GI lumen wall. In response to sufficient movement of the piston-needle assembly 120 (e.g., sufficient penetration into the GI lumen wall), the valve member 118 opens to allow the fluid formulation 116 to flow from the reservoir defined by the membrane 114 and the housing 112 into the chamber, where the fluid formulation 116 is directed through the piston-needle assembly 120 and into the GI lumen wall or its surrounding tissue.
[0068] The housing 102 and outer coating 104 (if present) are configured to allow ingestion of the device 100 and to temporarily protect the contents of the device 100 from degradation within one or more portions of the GI tract of a subject. The housing 102 can take a variety of different forms and shapes, such as a swallowable capsule (e.g., a size 00 capsule, a size 000 capsule, or other size capsule), or any other structure suitable for ingestion by a subject and that can house or contain one or more of the components of the device 100 (e.g., at least the member 106, the release member 108, and the delivery assembly 110 as discussed below). In one or more embodiments, the housing 102 includes two or more segments coupled (e.g., press-fit) together to define the housing 102. For example, the housing 102 can be configured as a capsule that includes a first segment that at least partially overlaps a second segment in a press-fit arrangement to define the housing 102. The first segment and the second segment can be removably coupled together to allow separation of the two segments. In one or more embodiments, expandable member 106, release 108, and delivery assembly 110 are each configured to be housed within an interior of housing 102. Release 108 may alternatively be positioned outside of the interior of housing 102, such as on an exterior portion of housing 102.
[0069] In one or more embodiments, the housing 102 can degrade under certain conditions. In addition, different portions of the housing 102 can be configured to degrade under different conditions or at different degradation rates, depending on the target site within the GI tract for delivery of the fluid formulation 116. For example, a portion or all of the housing 102 can include a material that degrades in water (e.g., in the presence of water in the form of moisture or humidity in the surrounding environment, such as in the body) and / or when exposed to a pH level above a particular threshold or within a particular range (e.g., a pH level associated with a desired location or portion of the GI tract, such as a pH level associated with a target site within the GI tract for delivery of the fluid formulation 116).
[0070] Optional outer coating 104 optionally covers a portion or all of shell 102. Outer coating 104 can include a single layer or multiple layers. Each layer can be formed by the same material or different materials. In one or more embodiments, outer coating 104 can be degraded under certain conditions, as described above with reference to shell 102. The example of outer coating 104 is an enteric coating, such as an enteric coating that degrades at a given rate in water and / or degrades when exposed to a solution with a pH level higher than a specific threshold or within a specific range. Another example of outer coating 104 is a protective coating (e.g., wax), such as a coating that protects a portion of the outer surface of shell 102 from contacting with a fluid or tissue (e.g., body tissue or fluid).
[0071] In one or more embodiments, degradation of the shell 102 and / or outer coating 104 allows fluid (e.g., bodily fluids in the stomach or intestines) to enter the interior of the shell 102 / outer coating 104 to activate the release member 108. Alternatively, the release member 108 can be positioned on an exterior portion of the shell 102, and degradation of the outer coating 104 can expose the release member 108 on the surface of the shell 102 to facilitate activation of the release member 108. Alternatively, the release member 108 can be positioned on a portion of the shell 102 that is devoid of the outer coating 104, and the release member 108 can be configured to degrade at a different rate and / or under different conditions than the shell 102 in the GI tract.
[0072] The shell 102 and / or the outer coating 104 can define one or more degradation zones for localized degradation of the shell 102 and / or the outer coating 104, for example, to allow controlled degradation and separation of the shell 102. For example, the outer coating 104 can be selectively applied only to certain areas of the shell 102 (e.g., on the ends of the shell 102) so as to expose selected portions of the shell 102 (e.g., the middle portion of the shell 102 between the ends), thereby defining areas of the shell 102 that can degrade at a faster rate and / or earlier than other areas of the shell 102. Such controlled degradation of the shell 102 can allow for more consistent separation of the shell 102, thereby allowing the fluid formulation 116 to be delivered into the GI lumen wall.
[0073] Expandable member 106 is a flexible and adjustable structure. In one or more embodiments, expandable member 106 is configured to expand from a collapsed state (e.g., folded, rolled up, flattened) to an expanded state for delivery of fluid formulation 116 in the desired position of the GI lumen. Expandable member 106 can have various shapes, sizes and configurations for temporary storage in shell 102 and for deployment in the lumen of the GI tract of a subject. Expandable member 106 can be configured as a balloon, bellows / accordion structure or any other structure that can be adjusted from a collapsed state to an expanded state.
[0074] Expandable member 106 is limited to the internal volume of the various components for accommodating device 100. For example, expandable member 106 can include (for example, comprise) one or more reactants temporarily separated from each other in internal volume. Internal volume is configured to promote by reactants mixed together (for example, in response to the activation of release piece 108) to form gas to cause the chemical reaction caused by the expansion of expandable member 106. Expandable member 106 can also include for making expandable member 106 deflate to promote expandable member 106 from the structure of experimenter's excretion when delivering fluid preparation 116. Expandable member 106 is configured to stretch limit amount and not perforate when expanding.
[0075] Expandable member 106 can be formed by one or more materials.Examples of suitable materials for expandable member 106 include hydroxypropyl methylcellulose (HPMC), polyvinyl acetate (PVA), lactide, glycolide, lactic acid, glycolic acid, p-dioxanone, trimethylene carbonate, caprolactone and mixtures and copolymers thereof.Expandable member 106 can include one or more layers of material.Expandable member 106 can be an integral structure.In other embodiments, expandable member 106 can be composed of one or more segments that are connected (for example, sealed or sutured) together.
[0076] The release member 108 is a chemical, mechanical, electrical, electromechanical, electrochemical, chemomechanical or electromechanical chemical structure. The release member 108 is configured to cause the expansion of the expandable member 106 when the release member 108 is activated. In one or more embodiments, the release member 108 is configured to be activated (e.g., degraded, released, moved, opened) in response to a condition in the GI tract. For example, the release member 108 can be configured to degrade in water so that the release member 108 can degrade when in contact with the fluid in the GI tract. For another example, the release member 108 can be configured to degrade at a specific pH level or above a specific pH level or within a pH level range associated with a position in the GI tract (e.g., pH in the stomach, pH in the intestine). In these and other embodiments, the release member 108 can be made of a biodegradable material (such as an enteric material). Additionally or alternatively, the release member 108 can be configured as a latch, a clip, a cover, a plug, a coating or any other structure that moves, opens or otherwise releases in response to a condition in the GI tract. The release member 108 can be formed of a single material or a combination of materials. The release member 108 can include one or more components. In embodiments where multiple components are included in the release member 108, the components can be co-located (e.g., coaxially) or can be physically separated from each other.
[0077] The delivery assembly 110 is a chemical, mechanical, electrical, electromechanical, electrochemical, chemomechanical or electromechanical chemical structure. In one or more embodiments, the delivery assembly 110 may include a housing 112, a membrane 114, a fluid formulation 116, a valve member 118 and a piston-needle assembly 120. In other embodiments, the delivery assembly 110 may include a housing 112, a membrane 114, a fluid formulation 116, a valve member 118 and a piston without a needle. In these embodiments, the delivery assembly 110 is configured to deliver the fluid formulation 116 from the housing 112 as a fluid jet, wherein the fluid jet has sufficient velocity to penetrate the GI luminal wall for systemic delivery of one or more therapeutic agents contained in the fluid formulation 116. Therefore, where the discussion herein relates to the piston-needle assembly 120, it should be understood that the piston-needle assembly 120 can be replaced with a piston without a needle.
[0078] The delivery assembly 110 is configured to be coupled to the expandable member 106 and (partially or completely) disposed in the expandable member 106. In response to the expansion of the expandable member 106, the delivery assembly 110 is also configured to deliver a fluid formulation 116 into the GI lumen wall or surrounding tissue thereof via the piston-needle assembly 120 or as a fluid jet from the housing 112. The device 100 may include one or more delivery assemblies 110 coupled to the expandable member 106 to allow for the delivery of one or more fluid formulations.
[0079] The housing 112 is configured to be coupled to the expandable member 106 and is in fluid communication with the expandable member 106. The housing 112 defines one or more chambers for movably receiving the piston-needle assembly 120. The outer portion of the housing 112 defines a recess, which cooperates with the membrane 114 to define a reservoir for accommodating a fluid preparation 116. The housing 112 includes one or more filling ports for filling the reservoir with the fluid preparation 116. The housing 112 is configured to allow gas pressure from within the expandable member 106 to be applied to the surface of the piston-needle assembly 120 so that the piston-needle assembly 120 moves axially relative to the housing 112. The housing 112 is also configured to engage with a valve member 118 (e.g., via one or more openings / seals) to allow the fluid preparation 116 to selectively flow from the reservoir into the one or more chambers, wherein the fluid preparation 116 is guided to the piston-needle assembly 120 to be delivered to the GI luminal wall or surrounding tissue. The housing 112 may include one or more vent ports to serve as a pressure relief device for the chamber of the housing 112. The housing 112 may include one or more components. In embodiments where multiple components are included in the housing 112, the components may be co-located or may be physically separated from each other.
[0080] Film 114 is a flexible structure. Film 114 is connected to housing 112. Film 114 and housing 112 cooperatively define a reservoir for accommodating fluid preparation 116. Reservoir can be limited to accommodate the volume of up to about 400 μl or more fluids (including 400 μl fluids). Reservoir can be limited to accommodate the volume of about 50 μl to about 300 μl fluids, including 50 μl to 300 μl fluids, such as 50 μl, 100 μl, 150 μl, 200 μl, 250 μl or 300 μl (or any value therebetween) fluid, or can accommodate 300 μl, 350 μl or 400 μl (or any value therebetween) fluid. Film 114 is also configured to respond to the pressure (for example, from the gas produced in expandable member 106) on the outer surface of film 114 by fluid preparation 116 discharged from reservoir to one or more chambers of housing 112.
[0081] Film 114 can have any suitable shape, such as annular, elliptical, spherical, cubic or other shapes. Film 114 can be formed by flexible or pliable material or otherwise include flexible or pliable material, to allow film 114 to deform (for example, by pressure bending) to discharge fluid preparation 116. The example of suitable material for film 114 includes polymeric material (for example, polyethylene terephthalate (PET)) or other flexible materials with sufficiently low moisture and gas permeability characteristics to be used together with fluid preparation 116. Film 114 can be formed by a combination of single material or material. In addition, film 114 can include one or more layers of material. Film 114 can be an integral structure. In other embodiments, film 114 can be formed by multiple segments that are connected (for example, sealed or sewn) together to limit film 114. Film 114 can include one or more components. In the embodiment of film 114, including multiple components, these components can be co-located or can be physically separated from each other.
[0082] Fluid formulation 116 is a formulation including one or more components, wherein the formulation is intended for treatment, diagnosis or other biological purposes. Fluid formulation 116 is in the form of a fluid, such as a liquid, slurry, gel, suspension (including colloidal suspension), gas, powder or any combination thereof. The fluid formulation 116 includes one or more components, which include one or more therapeutic agents, such as proteins, peptides, polypeptides, antibodies, drugs (e.g., selected from one or more of immunosuppressive drugs (e.g., adalimumab), chemotherapeutic drugs, central nervous system (CNS) drugs (e.g., anti-Parkinson's agents, antiemetics), anti-diabetic drugs (e.g., metformin), enzyme replacement therapy (ERT) drugs), hormones (e.g., parathyroid hormone (PTH), follicle stimulating hormone (FSH) and analogs thereof), insulin, incretins or combinations thereof (e.g., GLP-1, GLP-2, GIP, glucagon, PYY and analogs thereof), oligonucleotides (e.g., antisense oligonucleotides (ASOs), RNA interference (RNAi), aptamer RNA), DNA or siRNA transcripts, cells, cytotoxic agents, vaccines or other prophylactic agents, nutrients, vasodilators or vasoconstrictors, delivery enhancers, delay agents, excipients, diagnostic agents, or substances for cosmetic purposes. Fluid formulation 116 may include a therapeutically effective amount of one or more therapeutic agents as well as other components (eg, excipients) in suitable amounts to achieve a desired therapeutic effect in a subject.
[0083] The valve member 118 is a mechanical structure for selectively allowing the fluid preparation 116 to flow from the reservoir into the housing 112. The valve member 118 is configured to be arranged in the chamber of the housing 112. The valve member 118 can be connected to the housing 112. In other embodiments, the valve member 118 can be connected to the piston-needle assembly 120 or formed integrally with the piston-needle assembly 120. The valve member 118 is also configured to allow the fluid preparation 116 to flow from the reservoir into the chamber of the housing 112 in response to the sufficient axial movement of the piston-needle assembly 120. For example, the housing 112 may include an opening extending between the reservoir and the piston chamber. A seal can be connected at the opening to define a substantially fluid-tight seal between the reservoir and the piston chamber. The valve member 118 can be configured to be positioned in the piston chamber. The piercing member so that the sufficient axial movement of the piston-needle assembly 120 relative to the housing 112 causes the piercing member to pierce the seal to allow the fluid preparation 116 to flow from the reservoir into the piston chamber.
[0084] According to another example, the valve member 118 can be configured as a plug that is detachably coupled to the housing 112 at the opening. In this example, sufficient axial movement of the piston-needle assembly 120 relative to the housing 112 causes the plug to separate from the housing 112 to provide a fluid path for the fluid formulation 116 to flow from the reservoir into the piston chamber.
[0085] The valve member 118 can be formed of a single material or a combination of materials. Examples of suitable materials for the valve member 118 include polymeric materials (e.g., acrylonitrile butadiene styrene (ABS), polyetheretherketone (PEEK)), silicones, metals (e.g., stainless steel), or other materials or combinations of materials. The valve member 118 can include one or more components. In embodiments where multiple components are included in the valve member 118, the components can be located in the same location or can be physically separated from each other.
[0086] The piston-needle assembly 120 is a mechanical or mechanochemical structure. The piston-needle assembly 120 is movably (e.g., slidably) disposed in the housing 112. The piston-needle assembly 120 is configured to penetrate the GI luminal wall and deliver the fluid formulation 116 to the GI luminal wall or its surrounding tissue. The piston-needle assembly 120 can have a length sufficient to penetrate the GI luminal wall of the subject or its surrounding tissue to a desired depth. For example, the piston-needle assembly 120 can have a length sufficient to penetrate the GI luminal wall into the peritoneum or peritoneal cavity of the subject so as to discharge the fluid formulation 116 therein.
[0087] The piston-needle assembly 120 may include one or more components. For example, the piston-needle assembly 120 may include a piston, a shaft, and a needle. The piston-needle assembly 120 may include an inlet for receiving a fluid formulation 116 from within the housing and a channel for directing the fluid formulation 116 into the GI lumen wall.
[0088] The needle can be at least partially or completely degradable so that the needle can degrade in the GI lumen when delivering the fluid formulation 116. Suitable materials for the needle can include, for example, polyethylene oxide (PEO), magnesium, or other materials or combinations of materials. Suitable materials for the piston and shaft include, for example, polymeric materials (e.g., ABS), metals (e.g., titanium), or other materials or combinations of materials. In other embodiments, the needle can be substantially non-degradable or can include substantially non-degradable parts. In any embodiment, and particularly in embodiments where the needle is substantially non-degradable, the delivery assembly 110 can be equipped with a return spring or other structure to allow the needle to retract from the GI lumen wall into the housing 112 to prevent damage to the subject.
[0089] One or more components of the device 100 (e.g., housing 102, outer coating 104, expandable member 106, release member 108, delivery assembly 110) can be formed from or otherwise include one or more biodegradable materials to promote degradation of such components, e.g., to allow passage through the remainder of the subject's intestinal tract following delivery of the fluid formulation 116. Examples of biodegradable materials that may be suitable for use with the various components of the device 100 include, e.g., hydroxypropyl methylcellulose (HPMC), polyvinyl acetate (PVA), lactide, glycolide, lactic acid, glycolic acid, p-dioxanone, trimethylene carbonate, caprolactone, and mixtures and copolymers thereof.
[0090] The preceding description is an overview of the ingestible device 100. Figure 2-Figure 1 The following description of the apparatus 100 relates to examples of various features and aspects of the apparatus 100. These examples are intended to illustrate the apparatus 100 rather than to limit the apparatus 100.
[0091] refer to Figure 2 , shows a cross-sectional view of a device 200 (an embodiment of device 100) in an unfolded and / or unrolled state. Device 200 is shown without housing 102 and optional outer coating 104. However, it should be appreciated that device 200 can be folded, rolled, and / or otherwise manipulated to be disposed within housing 102 (optionally provided with outer coating 104) to allow device 200 to be ingested and subsequently delivered into the GI tract.
[0092] Device 200 includes an expandable member in the form of a balloon 202 (an embodiment of expandable member 106), a deflation valve 212, a reactant reservoir 214 containing a first reactant 215, a release member 216 (an embodiment of release member 108), a second reactant 217 and a delivery component 300 (an embodiment of delivery component 110).
[0093] Still reference Figure 2 The balloon 202 includes an inflatable segment 204, a deflated segment 205, a lower segment 206, and an elongated segment 210 extending between the inflatable segment 204 and the deflated segment 205. The lower segment 206 extends downward between the inflatable segment 204 and the deflated segment 205 (at Figure 2 215 and 216). The various segments of the balloon 202 cooperatively define an interior 202a for accommodating the various components of the device 200. As described below, the balloon 202 is configured to expand at a desired location within the lumen of the GI tract (e.g., stomach, intestine) in response to the formation of gas by a chemical reaction between the first reactant 215 and the second reactant 217 within the interior 202a. In this manner, the balloon 202 can facilitate the delivery of a fluid formulation 317 (an embodiment of the fluid formulation 116) from the delivery assembly 300 to the GI lumen wall or surrounding tissues thereof.
[0094] The balloon 202 has a size and shape that occupies a space in the GI lumen when the balloon 202 is inflated to allow for delivery of the fluid formulation 317 into the GI lumen wall. For example, when the balloon 202 is inflated, the periphery of the balloon 202 (e.g., the periphery of the lower segment 206 and the elongated segment 210) is pushed against the surface of the lumen wall. The pressure applied by the balloon 202 is sufficient to temporarily hold the balloon 202 relative to the lumen wall to deliver the fluid formulation 317. Depending on the inner circumference of the lumen delivery site, when the balloon 202 is inflated, the lower segment 206 can remain partially folded or can be fully extended. For example, if the lumen is relatively large and there are no obstructions that impede the expansion of the balloon 202, the balloon 202 will assume a fully inflated configuration with the lower segment 206 fully extended (e.g., Figure 2 ). However, if the lumen is relatively small, such that the inner lumen circumference is less than the maximum dimension of the fully inflated balloon 202, the lower section 206 will remain partially folded. In this manner, the balloon 202 can self-adjust to the size of the GI lumen to hold the balloon 202 in place for delivery of the fluid formulation 317, such that the same balloon 202 can be used with a wide range of lumen sizes (e.g., different inner circumferences).
[0095] The deflation valve 212 is configured to cause the deflation of the balloon 202 when the delivery of the fluid formulation 317 to the GI luminal wall or its surrounding tissue is completed. In this way, the deflation valve 212 can promote the balloon 202 to leave the anus of the subject by the remainder of the GI tract. In the illustrated embodiment, the deflation valve 212 is configured as a degradable plug, which temporarily covers the opening leading to the interior 202a. The degradable plug can be configured to degrade in response to contact with the fluid (e.g., body fluid) in the GI tract, thereby allowing the gas contained in the interior 202a to leave through the opening. For example, the deflation valve 212 can be formed by enteric material or include enteric material. The balloon 202 can include an optional winglet 228, which can temporarily cover the deflation valve 212 until the balloon 202 expands, thereby preventing the premature activation (e.g., degradation) of the deflation valve 212. For example, flap 228 can be temporarily held (e.g., adhered, stapled, or otherwise held) in folded position 228' about flap fold axis 228a. Expansion of balloon 202 can cause flap 228 to unfold from folded position 228' to expose deflation valve 212 and allow fluid in the GI tract to reach deflation valve 212 and cause deflation valve 212 to degrade, thereby providing an opening for gas, thereby allowing deflation.
[0096] The deflation valve 212 is shown as being located on the deflation section 205, but according to other embodiments, the deflation valve 212 can be located elsewhere on the expandable member 202. In addition, the balloon 202 can include more than one deflation valve 212. The deflation valve 212 can be configured differently. Figure 2 For example, in other embodiments, the deflation valve 212 can be configured as a degradable and / or removable cover disposed over an opening in the balloon 202. In these embodiments, degradation of the cover and / or movement away from the opening can cause gas to vent from the interior 202a through the opening, thereby allowing deflation.
[0097] Reactant reservoir 214 is arranged in interior 202a, and is configured to keep first reactant 215 therein and temporarily prevent first reactant 215 from contacting second reactant 217, and this second reactant 217 is arranged in interior 202a separately.First reactant 215 can be, for example, citric acid.Second reactant 217 can be, for example, carbonate, such as potassium bicarbonate.In other embodiments, first reactant 215 and second reactant 217 can be other types of reactants (for example, acid and alkali), which cause formation to be enough to expand sacculus 202 when mixing.Second reactant 217 is shown as being arranged in interior 202a at the inflation section 204 near first reactant 215.In other embodiments, first reactant 215 and second reactant 217 can be included in other regions of sacculus 202, as long as first reactant 215 and second reactant 217 are temporarily separated from each other.
[0098] Reactant reservoir 214 is limited to the internal volume for accommodating first reactant 215. Reactant reservoir 214 can take various forms and shapes, such as sacculus or other structures. Reactant reservoir 214 is communicated with inner 202a selective fluid via reactant conduit 218 and release 216. Release 216 is connected to reactant conduit 218 so that when activating (for example, degrading) release 216, first reactant 215 can leave and enter inner 202a from reactant reservoir 214 via reactant conduit 218. For example, release 216 can be the form of degradable plug, and this degradable plug blocks the inner part of reactant conduit 218 to temporarily prevent first reactant 215 from entering inner 202a. When the fluid in GI tract contacts release 216 (for example, when shell 102 and / or outer coating 104 degrade), release 216 can be degraded subsequently to allow reactant conduit 218 to discharge first reactant 215 into inner 202a.
[0099] In other embodiments, the device 200 includes a clip, a band or other structure for holding a portion of the balloon 202 in such a manner that a separate chamber for separately accommodating the first reactant 215 and the second reactant 217 is temporarily defined in the interior 202a. For example, a portion of the balloon 202 can be clamped or compressed by a degradable clip or band to temporarily define a separate chamber in the interior 202a. The chambers can be substantially sealed from each other to substantially prevent the first reactant 215 and the second reactant 217 from mixing. The clip or band can be located on the outer portion of the balloon 202 so that exposure to fluids in the GI tract (e.g., when the shell 102 and / or the outer coating 104 degrades) can cause degradation of the clip or band and subsequent release from the balloon 202. When the clip or band or the like is released from the balloon 202, the separated chambers are no longer substantially sealed from each other, thereby allowing the first reactant 215 to mix with the second reactant 217 in the interior 202a.
[0100] Combining the first reactant 215 with the second reactant 217 within the interior 202a causes a chemical reaction, resulting in the formation of a gas (e.g., CO2). The gas causes the balloon 202 to expand to an expanded state within the GI lumen, resulting in the elongated segment 210 being substantially aligned with the surface of the GI lumen wall. The substantial alignment of the elongated segment 210 relative to the GI lumen wall can advantageously help facilitate the delivery of the fluid formulation 317 from the delivery assembly 300 to the GI lumen wall or surrounding tissues thereof.
[0101] Still reference Figure 2, delivery assembly 300 is coupled to balloon 202 and is partially disposed within interior 202a. Delivery assembly 300 is shown to include housing 302 (an embodiment of housing 112), piercing member 308 (an embodiment of valve member 118), membrane 315 (an embodiment of membrane 114), fluid formulation 317 (an embodiment of fluid formulation 116), and piston-needle assembly 320 (an embodiment of piston-needle assembly 120). Membrane 315 and housing 302 cooperatively define a reservoir 315a for containing fluid formulation 317.
[0102] As described below, the gas pressurizing the balloon 202 can pass through one or more openings of the housing 302 to apply pressure to the surface of the piston-needle assembly 320. When the pressure reaches a threshold value (e.g., when the balloon 202 is fully or partially inflated), the pressure causes the piston-needle assembly 320 to move relative to the housing 302 to advance a portion of the piston-needle assembly 320 into the GI luminal wall or surrounding tissue. The gas pressurizing the balloon 202 is also applied to the outer surface of the membrane 315 for discharging the fluid formulation 317 into the housing 302. However, the reservoir 315a is substantially fluid-tight with the housing 112 to prevent the fluid formulation 317 from flowing from the reservoir 315a to the piston-needle assembly 320 until the piston-needle assembly 320 has traveled a sufficient distance. When the piston-needle assembly 320 has made sufficient axial travel relative to the housing 302 (e.g., upon penetrating the GI lumen wall), the piercing member 308 is configured to pierce the seal on the housing 302 to allow the fluid formulation 317 to flow from the reservoir 315a into the housing 302 and through the piston-needle assembly 320 for delivery to the GI lumen wall or surrounding tissue.
[0103] refer to Figure 3 , a detailed view of a portion of the device 200 including the delivery assembly 300 is shown. Figure 3 As shown, delivery assembly 300 includes housing 302, optional chamber seal 306, reservoir seal 307, piercing member 308, needle seal 309, cap 310, membrane 315, fluid formulation 317, and piston-needle assembly 320. Piston-needle assembly 320 is defined by piston 322, needle 324, and shaft 326. In other embodiments, piston-needle assembly 320 is a unitary structure including piston 322, needle 324, and shaft 326.
[0104] refer to Figure 3-Figure 5 The housing 302 includes a peripheral wall 302a, which defines a piston chamber 302a' and a needle chamber 302a". The piston 322 is movably (eg, slidably) disposed in the piston chamber 302a'. The needle 324 and a portion of the shaft 326 are disposed in the needle chamber 302a". Figure 3In the orientation shown, the needle chamber 302a" extends from the upper end of the piston chamber 302a'. The piston chamber 302a' has a generally cylindrical shape defining a first inner diameter D1, which corresponds to the outer diameter of the piston 322. Similarly, the needle chamber 302a" has a generally cylindrical shape defining a second inner diameter D2, which corresponds to the outer diameters of the needle 324 and the shaft 326. However, it should be understood that according to other embodiments, the piston chamber 302a' and the needle chamber 302a" can have different shapes other than cylindrical (e.g., oval, spherical). As shown in Figure 3 As shown, the first inner diameter D1 is greater than the second inner diameter D2, so that the peripheral wall 302a defines a step area 302aa extending between the upper end of the piston chamber 302a' and the lower end of the needle chamber 302a". The piston chamber 302a' and the needle chamber 302a" cooperatively define the longitudinal axis 302ab along which the piston-needle assembly 320 moves axially.
[0105] The housing 302 also includes an upper wall 302b extending outward (e.g., radially) from an upper section of the peripheral wall 302a that defines the needle chamber 302a". The housing 302 is configured to be connected to (e.g., heat sealed, adhered to) the balloon 202 (e.g., the elongated section 210) at the upper wall 302b. In the assembled state, the portion of the peripheral wall 302a located above the upper wall 302b extends outward from the elongated section 210 of the balloon 202 for positioning the needle chamber 302a" near the GI tube cavity wall. The upper wall 302b and a portion of the peripheral wall 302a (the portion extending from the upper wall 302b to the step area 302aa) together define a recess 304 extending circumferentially around the needle chamber 302a". As described below, the membrane 315 is connected to the housing 302 such that the membrane 315 surrounds the recess 304 to define a reservoir 315a for containing a fluid formulation 317 therein.
[0106] The upper wall 302b further defines one or more filling ports 302b' for filling the reservoir 315a with a fluid preparation 317. For example, in the illustrated embodiment, the upper wall 302b defines two filling ports 302b', which are configured as through holes for filling the reservoir 315a with a fluid preparation 317 (e.g., partially or completely). After filling the reservoir 315a, the filling port 302b' is sealed substantially fluid-tight using a separate seal 303 coupled thereto. The seal 303 may include, for example, silicone or aluminum foil. For example, the seal 303 may include a tube inserted into each filling port 302b' and a plug that is engaged with one side of the tube through the lateral opening of the housing 302 to form a pinch valve arrangement. In other embodiments, the filling port 302b' may include a diaphragm (e.g., a silicone diaphragm) so that the filling port 302b' can be self-sealed after filling the reservoir 315a with a fluid preparation 317. In any case, the reservoir 315a can be filled with the fluid formulation 317 before the delivery assembly 300 is coupled to the balloon 202. This can advantageously allow for flexibility associated with the aseptic assembly of the device 200. For example, before the delivery assembly 310 is coupled to the balloon 202, a vacuum can be applied to the reservoir 315a via the fill port 302b' in a sterile environment to substantially evacuate the reservoir 315a. The evacuated reservoir 315a can then be filled with the fluid formulation 317 via the fill port 302b' in a sterile environment prior to assembly with the balloon 202.
[0107] Still reference Figure 3-Figure 5 , the peripheral wall 302a further defines an opening 302a"' extending between the reservoir 315a and the piston chamber 302a' at the step area 302aa. The reservoir seal 307 is connected (e.g., adhered) to the peripheral wall 302a at the opening 302a"' to define a substantially fluid-tight seal between the reservoir 315a and the piston chamber 302a'. In this manner, the reservoir seal 307 substantially prevents the fluid formulation 317 from entering the piston chamber 302a' through the opening 302a"'. The reservoir seal 307 can be formed from a penetrable material such as aluminum foil.
[0108] The peripheral wall 302a and / or the upper wall 302b may further define one or more vent ports for venting the piston chamber 302a' or the balloon interior 202a during or after axial movement of the piston-needle assembly 320. The vent ports may be in selective fluid communication with the GI luminal environment external to the device 200. Additionally or alternatively, the peripheral wall 302a may include a ramp or other localized protrusion extending from its inner surface for pushing against the piston seal 323 upon sufficient axial movement of the piston 322 to create a fluid path through the piston chamber 302a' to allow ventilation of the balloon interior 202a to the GI luminal environment.
[0109] The piercing member 308 is disposed in the piston chamber 302a'. Figure 3-Figure 5 In the illustrated embodiment, the piercing member 308 is coupled to the peripheral wall 302a adjacent to the reservoir seal 307 by an adhesive tape 305 (e.g., polyimide tape). In other embodiments, the piercing member 308 can be coupled to the peripheral wall 302a by, for example, heat staking, ultrasonic welding, or other attachment means. Figure 3-Figure 5 In the illustrated embodiment, the piercing member 308 is configured as an elongated shaft having a tapered end (e.g., a pointed tip) with a structure similar to a tack. The piercing member 308 can be made of, for example, a polymer material (e.g., polyetheretherketone (PEEK)), a metal (e.g., stainless steel), or other materials or combinations of materials. Figures 3 to 5 In the illustrated embodiment, the tapered end of the piercing member 308 is positioned adjacent to the reservoir seal 307 by an adhesive strip 305 attached to the inner surface of the peripheral wall 302a. Figure 6 As discussed, the tapered end is configured to pierce the reservoir seal 307 in response to sufficient axial movement of the piston-needle assembly 320 relative to the housing 302 to allow the fluid formulation 317 to flow from the reservoir 315a into the piston chamber 302a'.
[0110] exist Figure 7-Figure 8 , another embodiment of the valve member 118 is shown as a piercing member 408. In this embodiment, the piercing member 408 is configured as a flexible tab. The piercing member 408 can be made of, for example, metal (e.g., stainless steel), a polymer material (e.g., PEEK), or other materials or combinations of materials. The piercing member 408 includes a planar end 408a that defines an opening 408a' for connecting the piercing member 408 to the peripheral wall 302a within the piston chamber 302a'. For example, the piercing member 408 can be heat riveted, ultrasonically welded, adhered, or otherwise attached to the peripheral wall 302a at the planar end 408a. The piercing member 408 also includes an elongated segment 408b extending away from the planar end 408a. The elongated segment 408b has a generally arcuate shape and extends downward at an acute angle relative to the planar end 408a (at Figure 8The elongated section 408b may also include one or more openings (e.g., slots) to further allow the fluid formulation 317 to flow through the opening 302a'".
[0111] The piercing member 408 also includes a tapered section 408c extending from the elongated section 408b. The tapered section 408c extends upwardly at an acute angle toward the planar end 408a (at Figure 8 The piercing member 408 is configured such that the tapered section 408c can pierce the reservoir seal 307 when the piston-needle assembly 320 is fully axially moved within the piston chamber 302a'. Figure 8 As shown, when the piston 322 moves axially within the piston chamber 302a', a portion of the piston 322 may engage the elongated segment 408b to deform or bend the elongated segment 408b relative to the planar end 408 (elastically or permanently). As a result, the tapered segment 408c may move toward the reservoir seal 307 to pierce the reservoir seal 307, thereby allowing the fluid formulation 317 to flow through the opening 302a'' into the piston chamber 302a'.
[0112] According to another embodiment, the valve member 118 can be configured as a barrel that includes a needle (or other feature with a pointed end) sufficient to pierce the reservoir seal 307. The barrel can be connected to the peripheral wall 302a adjacent to the reservoir seal 307 at least partially within the opening 302a″′. The barrel can be configured so that when the piston-needle assembly 320 engages the barrel during axial movement of the piston-needle assembly 320, the needle (or other feature) of the barrel can move toward the reservoir seal 307 to pierce the reservoir seal 307.
[0113] According to another embodiment, the valve member 118 can be defined by a portion of the piston-needle assembly 320. For example, the upper portion of the piston 322 can include a protrusion or other structural feature extending outwardly therefrom for piercing the reservoir seal 307 when the piston-needle assembly 320 travels a sufficient axial distance within the piston chamber 302a'. The protrusion or other feature can be coupled to the piston 322 or the shaft 326, or formed integrally with the piston 322 or the shaft 326.
[0114] according to Figures 9 and 10In another illustrated embodiment, the valve member 118 is in the form of a plug 508 rather than a piercing member. The plug 508 is removably coupled to the housing 302 at the opening 302a'". The plug 508 is illustrated as including a body 508a and a seal 508b coupled to or formed integrally with the body 508a. In other examples, the plug 508 may be a unitary structure. In the illustrated example, the seal 508b is configured to engage with the housing 302 at the opening 302a'" to create a substantially fluid-tight seal therebetween. For example, the seal 508b may be formed of or include a flexible polymer material, such as silicone. The body 508a has an elongated structure having a conical (e.g., truncated conical) shape to help form an interference fit with the housing 302 at the opening 302a'", thereby retaining the plug 508 on the housing 302. A portion of the body 508a extends into the piston chamber 302a' to engage with the surface of the piston 322 during axial movement of the piston 322. In this manner, the piston 322 can force the plug 508 to separate from the housing 302 to provide a fluid path from the reservoir 315a through the opening 302a'" to the piston chamber 302a', thereby discharging the fluid formulation 317.
[0115] For example, Fig.10 As shown, the piston-needle assembly 320 has traveled a sufficient distance with the piston chamber 302a' so that the upper surface of the piston 322 has engaged the body 508a of the plug 508. As a result, as shown in FIG. Fig.10 As shown by the unidirectional arrow 510 in FIG. 5 , the plug 508 is forced away from the opening 302 a ′″ and away from the housing 302 , thereby providing a fluid path from the reservoir 315 a through the opening 302 a ′″ to the piston chamber 302 a ′ for the fluid formulation 317 to flow therethrough.
[0116] Reference again Figure 3-Figure 5, the membrane 315 is coupled to the housing 302 to define a reservoir 315a. For example, the membrane 315 can be coupled to the housing 302 by heat sealing, ultrasonic welding, adhesion, or by other means. In the illustrated embodiment, the membrane 315 is coupled to the outer portion of the upper wall 302b and the outer portion of the peripheral wall 302a. The membrane 315 extends circumferentially around the needle chamber 302a" to surround the recess 304. In this manner, the membrane 315, the peripheral wall 302a and the upper wall 302b cooperate to define a reservoir 315a for containing a fluid formulation 317 therein. The reservoir 315a may contain up to about 400μl or more of fluid, including 400μl of fluid. The reservoir 315a may contain about 50μl to about 300μl of fluid, including 50μl to 300μl of fluid, such as 50μl, 100μl, 150μl, 200μl, 250μl or 300μl (or any value therebetween) of fluid, or may contain 300μl, 350μl or 400μl (or any value therebetween) of fluid. As described below, the membrane 315 is configured to be induced by gas pressure generated within the balloon 202 (from the first reactant 215 and the reaction of the second reactant 217) to deform (e.g., compress) to discharge the fluid preparation 317 from the reservoir 315a. The membrane 315 can have a relaxed shape or surface profile complementary to the outer surface profile of the housing 302 defining the recess 304 (i.e., when the reservoir 315a is not filled with the fluid preparation 317), so that the membrane 315 can be fully deformed to discharge most of the fluid preparation 317 from the reservoir 315a. In addition, this complementary shape of the membrane 315 can help promote the full emptying of the reservoir 315a so that it can be filled with the fluid preparation 317 during assembly. The membrane 315 can be formed of a polymer material (e.g., polyethylene terephthalate (PET)) or other flexible materials or combinations of materials with sufficiently low moisture permeability and air permeability to be used with the fluid preparation 317.
[0117] Optionally, a membrane shield can be coupled to the housing 302 to protect the membrane 315 from potential damage, such as during the assembly process of the device 200. The membrane shield can substantially surround the outer surface of the membrane 315. The membrane shield can be formed of a rigid or semi-rigid polymer material and can define a plurality of openings to provide a fluid path for the gas within the interior 202a to be applied against the outer surface of the membrane 315.
[0118] The piston-needle assembly 320 is disposed in the housing 302 and is configured to move axially relative to the housing 302 along the longitudinal axis 302ab. The piston-needle assembly 320 is defined by at least a piston 322, a needle 324, and a shaft 326. The piston-needle assembly 320 may also include a piston seal 323 and a shaft seal 325. In other embodiments, the piston-needle assembly 320 is an integral structure including the piston 322, the needle 324, and the shaft 326.
[0119] The piston 322 is movably (e.g., slidably) disposed in the piston chamber 302a'. The piston 322 defines an upper surface 322a and a lower surface 322b. The piston 322 is temporarily maintained in an axial position within the piston chamber 302a' by a release mechanism defined by the cover 310, the details of which will be discussed below. The piston 322 is configured to move axially within the piston chamber 302a' in response to a threshold gas pressure applied to the lower surface 322b within the balloon 202. The piston seal 323 can be connected to the outer peripheral side of the piston 322 between the upper surface 322a and the lower surface 322b or formed integrally with the outer peripheral side (e.g., insert molding). The piston seal 323 is configured to engage the inner surface of the peripheral wall 302a, thereby creating a substantially fluid-tight seal within the piston chamber 302a', between the piston 322 and the peripheral wall 302a. In this way, the piston seal 323 can help substantially prevent fluid (e.g., air, fluid formulation 317) from entering or leaving the area of the piston chamber 302a' located above the upper surface 322a. The piston seal 323 is further configured to allow the piston 322 to move axially relative to the peripheral wall 302a along the longitudinal axis 302ab within the piston chamber 302a'. The piston 322 can be formed of a polymer material (e.g., acrylonitrile butadiene styrene (ABS)) or other materials or combinations of materials. The piston seal 323 can be formed of silicone or other suitable materials.
[0120] The needle 324 is coupled to (e.g., press-fitted) the shaft 326 and the piston 322, or is integrally formed with (e.g., insert molded) the shaft 326 and the piston 322. Figure 3 In the unactuated state shown, the needle 324 is temporarily disposed within the needle chamber 302a". The needle seal 309 is coupled (e.g., adhered) to the peripheral wall 302a at the upper end of the needle chamber 302a" to substantially prevent fluid in the GI tract from entering the needle chamber 302a" until the needle 324 pierces the needle seal 309. The needle seal 309 can be formed from a penetrable material (e.g., aluminum foil) to allow the needle 324 to pierce the needle seal 309. In this manner, the needle seal 309 and the peripheral wall 302a can cooperatively define a substantially sterile environment within the needle chamber 302a" for accommodating the needle 324 prior to delivering the fluid formulation 317 into the GI luminal wall or surrounding tissue.
[0121] like Figure 3-Figure 5As shown, the needle 324 includes a tapered section 324a (e.g., a pointed tip) configured to pierce the needle seal 309 and penetrate the GI lumen wall in response to sufficient axial movement of the piston 322. The needle 324 also includes an elongated section 324b extending from the tapered section 324a. The elongated section 324b may be coupled to the tapered section 324a or formed integrally with the tapered section 324a. The elongated section 324b defines a needle channel 324b' extending from the needle opening 324a' to the opposite end of the elongated section 324b. As shown in FIG. Figure 3 As shown, the tapered section 324a defines a needle opening 324a' extending through the end of the tapered section 324a for discharging the fluid preparation 317 into the GI luminal wall or surrounding tissue. Additionally or alternatively, the elongated section 324b includes a side opening (e.g., a slotted opening) for discharging the fluid preparation 317 into the GI luminal wall or surrounding tissue. In some embodiments, the needle 324 is at least partially or may be completely degradable so that at least a portion of the needle 324 can be substantially degraded within the GI luminal wall (or other locations in the GI tract) when the fluid preparation 317 is delivered. For example, the needle 324 can be formed of polyethylene oxide (PEO), magnesium or other degradable materials or combinations of materials or otherwise include polyethylene oxide (PEO), magnesium or other degradable materials or combinations of materials.
[0122] In other embodiments, the needle 324 can be formed from a substantially non-degradable material, such as polyetheretherketone (PEEK) or a combination of materials, or other materials or combinations of materials. In these and other embodiments, the needle 324 can include a tip formed from a degradable material, such as magnesium, to allow for biodegradation of at least the tip within the patient's body. In embodiments where the needle 324 is substantially non-degradable or includes a substantially non-degradable portion, the device 200 is configured to retract the needle 324 within the housing 302 upon completion of delivery of the fluid formulation 317. For example, the device 200 can include a return spring or other biasing member coupled to the needle 324 for retracting the needle 324 within the housing 302 after delivery of the fluid formulation 317.
[0123] Axis 326 is coupled to piston 322 and needle 324 (e.g., press fit, adhesion) or is formed integrally with piston 322 and needle 324. In one or more embodiments, shaft 326 and piston 322 can define an integral structure. In the illustrated embodiment, shaft 326 is configured as a generally cylindrical member with a generally elongated configuration, although other shapes and configurations can be envisioned according to other embodiments. Axis 326 extends from first end 326a to second end 326b. First end 326a is coupled to needle 324 (e.g., press fit, adhesion, insert molding) or is formed integrally with needle 324. Second end 326b is coupled to piston 322 or is formed integrally with piston 322. Axis 326 also defines an inlet 326b' for receiving fluid preparation 317 from piston chamber 302a' and an inner shaft channel 326a' for guiding fluid preparation 317 from inlet 326b' to needle channel 324b'. The inlet 326b' extends radially from the outer surface of the shaft 326 to the inner shaft channel 326a'. The inner shaft channel 326a' extends longitudinally along the longitudinal axis 302ab. In other embodiments, the shaft 326 may include multiple inlets and / or channels for directing the fluid formulation 317 to the needle channel 324b'.
[0124] The shaft seal 325 can be coupled to an outer portion of the shaft 326 (e.g., press fit, adhesion) or formed integrally with an outer portion of the shaft 326 (e.g., insert molding). The shaft seal 325 is located on a circumferential ridge 326e of the shaft 326 above the inlet 326c. The shaft seal 325 is configured to engage the inner surface of the peripheral wall 302a between the piston chamber 302a' and the needle chamber 302a" to create a substantially fluid-tight seal between the piston chamber 302a' and the needle chamber 302a" when the piston-needle assembly 320 is fully axially advanced relative to the housing 302. In this manner, the shaft seal 325 can help prevent the fluid formulation 317 from entering the needle chamber 302a from the piston chamber 302a'. The shaft seal 325 can also be used to limit the axial travel of the piston-needle assembly 320 within the piston chamber 302a' to help define the fluid passage 312 between the upper surface of the piston 322 and the inner surface of the peripheral wall 302a within the piston chamber 302a' (see Figure 6 ). For reference, see below Figure 6 As discussed, fluid channel 312 may be used to direct fluid formulation 317 from opening 302a'" to inlet 326c within piston chamber 302a'. In other embodiments, piston 322 may define a fluid channel in upper surface 322a for directing fluid formulation 317 to inlet 326c.
[0125] In other embodiments, the housing 302 and / or piston 322 may include one or more features (e.g., stand-off features, stop features, protrusions) to limit axial travel of the piston-needle assembly 320 within the piston chamber 302a' to help define the fluid passage 312.
[0126] The delivery assembly 300 optionally includes a lubricant seal 306 coupled to the inner surface of the peripheral wall 302a within the piston chamber 302a'. The lubricant seal 306 can help minimize interaction between the fluid formulation 317 and lubricant that may be present within the piston chamber 302a' (e.g., on the piston seal 323), which can help minimize contamination of the fluid formulation 317. Figure 5 As shown, the lubricant seal 306 extends circumferentially within the piston chamber 302a ′. In other embodiments, the lubricant seal 306 is coupled to the piston-needle assembly 320 .
[0127] The cover 310 is coupled to the housing 302 at the open end of the piston chamber 302a'. The cover 310 is also removably coupled to the piston-needle assembly 320 by a release mechanism that temporarily holds the piston-needle assembly 320 in an axial position within the piston chamber 302a'. Figure 3-Figure 5 In the illustrated embodiment, the cap 310 includes a first cap segment 310a coupled to the peripheral wall 302a and a second cap segment 302b coupled (e.g., heat staking, ultrasonic welding) to the piston-needle assembly 320. The first cap segment 310a is removably coupled to the second cap segment 310b by one or more tabs 310c defining a release mechanism. For example, the tabs 310c can define a frangible connection between the first cap segment 310a and the second cap segment 310b.
[0128] like Figure 5As shown, tabs 310c are circumferentially spaced around second cover segment 310b and define a plurality of openings 310a'. Openings 310a' can allow gas generated within interior 202a of balloon 202 to be applied to lower surface 322b of piston 322. According to other embodiments, cover 310 can include one or more openings disposed in other portions of cover 310. When the gas pressure applied to piston 322 reaches a threshold, tabs 310c are configured to break from at least one of first cover segment 310a or second cover segment 310b, thereby allowing piston-needle assembly 320 to move axially along longitudinal axis 302ab within piston chamber 302a' toward piercing member 308. The threshold pressure value can be a pressure associated with a fully expanded state of balloon 202, such that before needle 324 is advanced into the GI lumen wall, e.g., before tabs 310c break to allow piston-needle assembly 320 to move axially toward piercing member 308, elongated segment 210 is substantially aligned relative to the GI lumen wall.
[0129] According to another embodiment, the release mechanism of the cap 310 can be defined by one or more snap features that removably couple the cap 310 to the piston-needle assembly 320. Similar to the tab 310c described above, the one or more snap features can be configured to separate from the piston-needle assembly 320 and / or from the cap 310 in response to a threshold gas pressure applied to the piston-needle assembly 320 to allow the piston-needle assembly 320 to move axially away from the cap 310 and toward the piercing member 308 to advance the needle 324 into the GI lumen wall.
[0130] According to another embodiment, the release mechanism of the cap 310 can be defined by one or more flexible tabs extending from the cap 310 toward the longitudinal axis 302ab. The one or more flexible tabs can overlap with complementary features (e.g., protrusions) on the piston-needle assembly 320 to define an interference condition. In this embodiment, the one or more tabs can be deflected in response to a threshold gas pressure applied to the piston-needle assembly 320 to allow the piston-needle assembly 320 to overcome the interference condition with the one or more tabs and allow the piston-needle assembly 320 to move axially away from the cap 310 and toward the piercing member 308 to advance the needle 324 into the GI lumen wall.
[0131] refer to Figure 6 , shows a portion of the device 200 including the delivery assembly 300 after the device 200 has reached a desired location in the GI tract (e.g., the stomach or small intestine) where a fluid formulation 317 needs to be delivered. Figure 6As shown, the balloon 202 has been inflated by gas generated within the interior 202a so that the elongated section 210 is substantially aligned with the GI lumen wall. The gas generated within the interior 202a applies pressure (indicated by the unidirectional arrow 330) to the outer surface of the membrane 315 and to the lower surface 322b of the piston 322 through the opening 310a' of the cover 310. When the gas pressure reaches a threshold value (e.g., a pressure associated with a fully or partially inflated state of the balloon 202), the piston 322 is separated from the cover 310 via the removable tab 310c to allow the piston-needle assembly 320 to move axially relative to the housing 302 along the longitudinal axis 302ab toward the piercing member 308 so that the needle 324 pierces the needle seal 309 to penetrate the GI lumen wall. In this embodiment, while the gas pressure is applied to the outer surface of the membrane 315, the fluid formulation 317 is retained in the reservoir 315a until the needle 324 fully penetrates the GI lumen wall or surrounding tissue (e.g., reaches a desired penetration depth)
[0132] When needle 324 has sufficiently penetrated the GI lumen wall or surrounding tissue, piston 322 engages piercing member 308 to cause piercing member 308 to pierce reservoir seal 307 . As a result, the gas pressure within the interior 202a applied to the outer surface of the membrane 315 causes the fluid formulation 317 to flow from the reservoir 315a into the piston chamber 302a' through the opening 302a'". The fluid formulation 317 is directed to the inlet 326b' of the shaft 326 through the fluid channel 312. The piston seal 323 and the shaft seal 325 can help control the fluid formulation 317 within the fluid channel 312. The gas pressure applied to the membrane 315 further causes the fluid formulation 317 to flow through the inlet 326b', the internal shaft channel 326a' and the needle channel 324b', so that the needle 324 discharges the fluid formulation 317 from the needle opening 324a' into the GI luminal wall or surrounding tissue thereof. In this manner, one or more therapeutic agents contained in the fluid formulation 317 can be delivered to the bloodstream of the subject.
[0133] In other embodiments, the device 200 can be configured so that the fluid preparation 317 is discharged into the piston chamber 302a' and the needle 324 penetrates the GI luminal wall substantially simultaneously. For example, this can be adjusted by selecting the length of the needle 324, the length of the shaft 326, the position of the piercing member 308, the size of the housing 302, or otherwise adjusting the axial stroke amount of the piston-needle assembly 320 in the piston chamber 302a' so that the stroke amount required to pierce the seal 307 via the piercing member 308 substantially corresponds to the stroke amount required for the needle 324 to penetrate the GI luminal wall. Configuring the device 200 so that the piercing member 308 pierces the seal 307 after or substantially simultaneously with the needle 324 penetrating the GI luminal wall can advantageously help prevent the fluid preparation 317 from being discharged into the luminal environment to ensure that the majority of the fluid preparation 317 is delivered to the GI luminal wall or surrounding tissue. In other words, the device 200 can allow for sequential timing between penetrating the GI luminal wall and discharging the fluid preparation 317 to substantially avoid discharging the fluid preparation 317 into the luminal environment.
[0134] After delivery of the fluid formulation 317 is completed, the needle 324 can then degrade with one or more additional components of the device 200 (e.g., housing 302, membrane 315, shaft 326, piston 322, cap 310) in the GI lumen wall or other area within the GI tract. In embodiments where the needle 324 is substantially non-degradable, the device 200 is configured to retract the needle 324 within the housing 302 upon completion of delivery of the fluid formulation 317. For example, the device 200 can include a return spring or other biasing member coupled to the needle 324 for retracting the needle 324 within the housing 302 after delivery of the fluid formulation 317. In any of these embodiments, the deflation valve 212 can release a large amount of gas contained within the interior 202a to allow a large amount of deflation of the balloon 202 and subsequent passage of the device 200 through the remainder of the GI tract to exit the anus of the subject.
[0135] Reference now Fig.11, a method 600 of delivering a fluid formulation 116 to a subject's GI tract using a device 100 is shown. In a first step, the subject ingests the device 100 (e.g., by swallowing the device 100) (step 601). As a result of ingestion, when the device 100 reaches a desired position in the GI tract where the fluid formulation 116 needs to be delivered, the housing 102 and / or the outer coating 104 are at least partially (or may be completely) degraded (step 602). In response to the degradation of the housing 102 and / or the outer coating 104, the release member 108 is activated to expand the expandable member 106 within the GI lumen (step 603). The expansion of the expandable member 106 within the GI lumen causes the delivery assembly 110 to be positioned close to the GI lumen wall (step 604). When the gas pressure within the expandable member 106 reaches a threshold value, the gas pressure moves the piston-needle assembly 120 relative to the housing 112 to advance a portion of the piston-needle assembly 120 into the GI lumen wall or its surrounding tissue (step 605). When the piston-needle assembly 120 travels a sufficient axial distance relative to the housing 112, the valve member 118 opens to allow the fluid formulation 116 to flow into the housing 112 (step 606). The gas pressure within the expandable member 106 is applied to the membrane 114 to expel the fluid formulation 116 into the housing 112 through the piston-needle assembly 120 and then deliver it to the GI luminal wall or surrounding tissue (step 607). In this way, the device 100 can deliver one or more therapeutic agents contained in the fluid formulation 116 to the subject's bloodstream for systemic delivery.
[0136] The foregoing description of various embodiments has been presented for purposes of illustration and description. It is not intended to limit the invention to the precise form disclosed. Many modifications, variations, and improvements will be apparent to those skilled in the art. For example, embodiments of the device may be sized and otherwise adapted to various pediatric and neonatal applications and various veterinary applications. In addition, those skilled in the art will recognize or be able to determine many equivalents to the specific devices and methods described herein using only routine experimentation. Such equivalents are considered to be within the scope of this disclosure.
[0137] Although the present disclosure has been described and illustrated with reference to specific embodiments of the present disclosure, these descriptions and illustrations do not limit the present disclosure. It is clearly understood that various changes can be made and equivalent components can be replaced within the embodiments without departing from the true spirit and scope of the present disclosure as defined by the appended claims. Similarly, components, characteristics or actions from one embodiment can be easily recombined or replaced with one or more components, characteristics or actions from other embodiments to form many additional embodiments within the scope of the present invention. In addition, in various embodiments, components shown or described as being combined with other components can exist as independent components. In addition, for any positive description of components, characteristics, ingredients, features, steps, etc., embodiments of the present invention also specifically consider excluding the components, values, characteristics, ingredients, features, steps, etc. The illustrations may not necessarily be drawn to scale. Due to variables such as manufacturing processes, there may be differences between the technical reproduction in the present disclosure and the actual device. There may be other embodiments of the present disclosure that are not specifically shown. The specification and drawings should be regarded as illustrative rather than restrictive. Modifications can be made to adapt specific situations, materials, material compositions, methods or processes to the purpose, spirit and scope of the present disclosure. All such modifications are intended to fall within the scope of the appended claims. Although the methods disclosed herein have been described with reference to specific operations performed in a specific order, it is understood that these operations may be combined, subdivided, or reordered to form equivalent methods without departing from the teachings of the present disclosure. Therefore, unless otherwise specifically noted herein, the order and grouping of operations are not limitations of the present disclosure.
Claims
1. A delivery assembly for an ingestible device for delivering a fluid formulation into a GI luminal wall or surrounding tissue of a subject, the delivery assembly comprising: a housing defining a chamber; a piston-needle assembly movably disposed in the chamber, the piston-needle assembly comprising an inlet and a passage; a membrane coupled to the housing such that the membrane and the housing cooperatively define a reservoir for containing the fluid formulation, wherein the housing further defines an opening extending between the chamber and the reservoir; and a valve member for selectively controlling the flow of the fluid formulation from the reservoir to the chamber through the opening; wherein, in response to sufficient movement of the piston-needle assembly relative to the housing, the valve member opens to allow the fluid formulation to flow from the reservoir through the opening into the chamber; and Therein, the fluid formulation is guided from the chamber to the inlet and the channel for delivery to the GI luminal wall or surrounding tissues thereof.
2. The delivery assembly of claim 1, wherein: The piston-needle assembly and the housing cooperatively define a fluid passage within the chamber for directing the fluid formulation from the opening to the inlet.
3. The delivery assembly of claim 1, wherein: The valve member includes a plug removably coupled to the housing at the opening.
4. The delivery assembly of claim 3, wherein: The piston-needle assembly engages the stopper to disengage the stopper from the housing to allow the fluid formulation to flow from the reservoir through the opening into the chamber.
5. The delivery assembly of claim 1, wherein: The valve member includes a piercing member and a seal, and wherein the seal is coupled to the housing at the opening.
6. The delivery assembly of claim 5, wherein: The piston-needle assembly engages the piercing member such that the piercing member pierces the seal, thereby allowing the fluid formulation to flow from the reservoir through the opening into the chamber.
7. The delivery assembly of claim 5, wherein: The piercing member is configured as a flexible tab having a tapered end.
8. The delivery assembly of claim 5, wherein: The piercing member is configured as an elongated shaft having a tapered end.
9. The delivery assembly of claim 1, wherein: The delivery assembly is configured to be coupled to and disposed within the expandable member.
10. The delivery assembly of claim 1, wherein: The delivery assembly is configured to be contained in an ingestible housing for delivery to the GI tract of the subject.
11. The delivery assembly of claim 1, wherein: The piston-needle assembly is configured to move relative to the housing in response to gas pressure applied to a surface of the piston-needle assembly to advance a portion of the piston-needle assembly into the GI lumen wall or surrounding tissue.
12. The delivery assembly of claim 1, wherein: The piston-needle assembly is configured to penetrate the GI lumen wall into the peritoneum or peritoneal cavity of the subject to discharge the fluid formulation in the peritoneum or peritoneal cavity.
13. The delivery assembly of claim 1, wherein: The reservoir defines a volume for containing up to about 400 μl of fluid.
14. The delivery assembly of claim 1, wherein: The reservoir defines a volume for containing about 50 μl to about 300 μl of fluid.
15. The delivery assembly of claim 1, further comprising a cap coupled to the housing, the cap defining a release mechanism for temporarily retaining the piston-needle assembly in an axial position relative to the housing.
16. The delivery assembly of claim 15, wherein: The cover includes a first cover segment coupled to the housing and a second cover segment coupled to the piston-needle assembly, and wherein the release mechanism is defined by one or more tabs removably coupled between the first cover segment and the second cover segment.
17. The delivery assembly of claim 16, wherein:The cover also includes one or more openings to allow gas pressure to be applied to a surface of the piston-needle assembly, and wherein the one or more tabs are configured to separate from at least one of the first cover segment or the second cover segment to allow the piston-needle assembly to move axially relative to the housing in response to the gas pressure reaching a threshold.
18. The delivery assembly of claim 1, wherein: The membrane extends circumferentially around the housing.
19. The delivery assembly of claim 1, wherein: The membrane comprises a flexible material to allow the membrane to be deformed by gas pressure applied to an outer surface of the membrane to expel the fluid formulation from the reservoir into the chamber.
20. The delivery assembly of claim 1, wherein: The housing includes one or more fill ports for filling the reservoir with the fluid formulation.
21. The delivery assembly of claim 1, further comprising a fluid formulation disposed in the reservoir, wherein the fluid formulation comprises at least one therapeutic agent.
22. The delivery assembly of claim 21, wherein: The at least one therapeutic agent is selected from one or more of an immunosuppressive drug, a chemotherapeutic drug, a central nervous system (CNS) drug, an anti-diabetic drug, an enzyme replacement therapy (ERT) drug, an antibody, a hormone, insulin, an incretin or a combination thereof, or an oligonucleotide.
23. An ingestible device for delivering a fluid formulation into a GI lumen wall or surrounding tissue of a subject, the ingestible device comprising: Extensible components; and a delivery assembly coupled to and disposed within the expandable member, the delivery assembly comprising: a housing defining a chamber; a piston-needle assembly movably disposed in the chamber, the piston-needle assembly comprising an inlet and a passage; a membrane coupled to the housing such that the membrane and the housing cooperatively define a reservoir, wherein the housing further defines an opening extending between the chamber and the reservoir; a fluid formulation disposed in the reservoir, the fluid formulation comprising at least one therapeutic agent; and a valve member for selectively controlling the flow of the fluid formulation from the reservoir to the chamber through the opening; wherein, in response to sufficient movement of the piston-needle assembly relative to the housing, the valve member opens to allow the fluid formulation to flow from the reservoir through the opening into the chamber; and The fluid formulation is guided from the chamber to the inlet and the channel for delivery to the GI luminal wall or surrounding tissues thereof.
24. The device according to claim 23, wherein: The piston-needle assembly and the housing cooperatively define a fluid passage within the chamber for directing the fluid formulation from the opening to the inlet.
25. The device according to claim 23, wherein: The valve member includes a plug removably coupled to the housing at the opening.
26. The device according to claim 25, wherein The piston-needle assembly engages the stopper to disengage the stopper from the housing to allow the fluid formulation to flow from the reservoir through the opening into the chamber.
27. The device according to claim 23, wherein: The valve member includes a piercing member and a seal, and wherein the seal is coupled to the housing at the opening.
28. The device according to claim 27, wherein The piston-needle assembly engages the piercing member such that the piercing member pierces the seal, thereby allowing the fluid formulation to flow from the reservoir through the opening into the chamber.
29. The device according to claim 27, wherein: The piercing member is configured as a flexible tab having a tapered end.
30. The device according to claim 27, wherein: The piercing member is configured as an elongated shaft having a tapered end.
31. The device of claim 23, further comprising an ingestible housing for delivery into the GI tract of the subject.
32. The device according to claim 23, wherein: The expandable member includes a balloon.
33. The apparatus of claim 32, further comprising a plurality of reactants disposed within the balloon for generating gas pressure within the balloon to expand the balloon within the GI lumen.
34. The device according to claim 33, wherein: The piston-needle assembly is configured to move relative to the housing in response to gas pressure applied to a surface of the piston-needle assembly to advance a portion of the piston-needle assembly into the GI lumen wall or surrounding tissue.
35. The device according to claim 33, wherein The membrane comprises a flexible material to allow the membrane to be deformed by gas pressure applied to an outer surface of the membrane to expel the fluid formulation from the reservoir into the chamber.
36. The apparatus of claim 23, wherein: The piston-needle assembly is configured to penetrate the GI lumen wall into the peritoneum or peritoneal cavity of the subject to discharge the fluid formulation in the peritoneum or peritoneal cavity.
37. The apparatus of claim 23, wherein: The reservoir defines a volume for containing up to about 400 μl of fluid.
38. The apparatus of claim 23, wherein: The reservoir defines a volume for containing about 50 μl to about 300 μl of fluid.
39. The apparatus of claim 22, wherein: The delivery assembly also includes a cap coupled to the housing, the cap defining a release mechanism for temporarily retaining the piston-needle assembly in an axial position relative to the housing.
40. The device according to claim 39, wherein The cover includes a first cover segment coupled to the housing and a second cover segment coupled to the piston-needle assembly, and wherein the release mechanism is defined by one or more tabs removably coupled between the first cover segment and the second cover segment.
41. The device according to claim 40, wherein The cover also includes one or more openings to allow gas pressure to be applied to a surface of the piston-needle assembly, and wherein the one or more tabs are configured to separate from at least one of the first cover segment or the second cover segment to allow the piston-needle assembly to move axially relative to the housing in response to the gas pressure reaching a threshold.
42. The apparatus of claim 23, wherein: The membrane extends circumferentially around the housing.
43. The apparatus of claim 23, wherein: The housing includes one or more fill ports for filling the reservoir with the fluid formulation.
44. The apparatus of claim 23, wherein: The at least one therapeutic agent is selected from one or more of an immunosuppressive drug, a chemotherapeutic drug, a central nervous system (CNS) drug, an anti-diabetic drug, an enzyme replacement therapy (ERT) drug, an antibody, a hormone, insulin, an incretin or a combination thereof, or an oligonucleotide.
45. A method for delivering a fluid formulation into the GI lumen wall or surrounding tissue of a subject in need thereof, comprising ingesting by the subject an ingestible device according to any one of claims 23-44.
46. Use of an ingestible device according to any one of claims 23-44 for delivering a fluid formulation comprising a therapeutic agent into the GI lumen wall or surrounding tissue of a subject in need thereof.
47. A method of preparing an ingestible device for delivering a therapeutic agent to a GI lumen wall or surrounding tissue of a subject, the method comprising filling a fluid formulation comprising the therapeutic agent into a delivery assembly according to any one of claims 1-22.
